Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1994-9-21
pubmed:abstractText
Thapsigargin (TG), 2,5-t-butylhydroquinone (tBHQ) and cyclopiazonic acid (CPA) all inhibit the initial Ca(2+)-response to thyrotropin-releasing hormone (TRH) by depleting intracellular Ca2+ pools sensitive to inositol 1,4,5-trisphosphate (IP3). Treatment of GH3 pituitary cells for 30 min with 5 nM TG, 500 nM tBHQ or 50 nM CPA completely eliminated the TRH-induced spike in intracellular free Ca2+ ([Ca2+]i). Higher concentrations of TG and tBHQ, but not CPA, were also found to inhibit strongly the activity of L-type calcium channels, as measured by the increase in [Ca2+]i or 45Ca2+ influx stimulated by depolarization. TG and tBHQ blocked high-K(+)-stimulated 45Ca2+ uptake, with IC50 values of 10 and 1 microM respectively. Maximal inhibition of L-channel activity was achieved 15-30 min after drug addition. Inhibition by tBHQ was reversible, whereas inhibition by TG was not. TG and CPA did not affect spontaneous [Ca2+]i oscillations when tested at concentrations adequate to deplete the IP3-sensitive Ca2+ pool. However, 20 microM TG and 10 microM tBHQ blocked [Ca2+]i oscillations completely. The effect of drugs on calcium currents was measured directly by using the patch-clamp technique. When added to the external bath, 10 microM CPA caused a sustained increase in the calcium-channel current amplitude over 8 min, 10 microM tBHQ caused a progressive inhibition, and 10 microM TG caused an enhancement followed by a sustained block of the calcium current over 8 min. In summary, CPA depletes IP3-sensitive Ca2+ stores and does not inhibit voltage-operated calcium channels. At sufficiently low concentrations, TG depletes IP3-sensitive stores without inhibiting L-channel activity, but, for tBHQ, inhibition of calcium channels occurs at concentrations close to those needed to block agonist mobilization of intracellular Ca2+.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1279382, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1288328, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1314042, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1319898, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1328177, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1463451, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1530936, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1531101, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1531138, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1535599, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1659864, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1662401, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1831452, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1832668, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-1834651, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-2138778, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-2440312, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-2444888, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-2517986, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-2551046, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-2906142, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-2936465, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-2961610, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-3325037, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-3925349, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-4951281, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-7684897, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-7686480, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-8218284, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-8245023, http://linkedlifedata.com/resource/pubmed/commentcorrection/7520693-8262009
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/2,5-di-tert-butylhydroquinone, http://linkedlifedata.com/resource/pubmed/chemical/3-Pyridinecarboxylic acid..., http://linkedlifedata.com/resource/pubmed/chemical/Calcium, http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers, http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channels, http://linkedlifedata.com/resource/pubmed/chemical/Calcium-Transporting ATPases, http://linkedlifedata.com/resource/pubmed/chemical/Hydroquinones, http://linkedlifedata.com/resource/pubmed/chemical/Indoles, http://linkedlifedata.com/resource/pubmed/chemical/Inositol 1,4,5-Trisphosphate, http://linkedlifedata.com/resource/pubmed/chemical/Potassium, http://linkedlifedata.com/resource/pubmed/chemical/Terpenes, http://linkedlifedata.com/resource/pubmed/chemical/Thapsigargin, http://linkedlifedata.com/resource/pubmed/chemical/cyclopiazonic acid
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0264-6021
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
302 ( Pt 1)
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
147-54
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Inhibition of L-type calcium-channel activity by thapsigargin and 2,5-t-butylhydroquinone, but not by cyclopiazonic acid.
pubmed:affiliation
Department of Pharmacology, University of Rochester School of Medicine and Dentistry, NY 14642.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.